Olfactory Dysfunction and Its Related Molecular Mechanisms in Parkinson's Disease

Overview

Journal Neural Regen Res

Date 2023 Sep 18

PMID 37721288

Authors

Yingying Gu

Jiaying Zhang

Xinru Zhao

Wenyuan Nie

Xiaole Xu

Mingxuan Liu

Xiaoling Zhang

Affiliations

Soon will be listed here.

Abstract

Changes in olfactory function are considered to be early biomarkers of Parkinson's disease. Olfactory dysfunction is one of the earliest non-motor features of Parkinson's disease, appearing in about 90% of patients with early-stage Parkinson's disease, and can often predate the diagnosis by years. Therefore, olfactory dysfunction should be considered a reliable marker of the disease. However, the mechanisms responsible for olfactory dysfunction are currently unknown. In this article, we clearly explain the pathology and medical definition of olfactory function as a biomarker for early-stage Parkinson's disease. On the basis of the findings of clinical olfactory function tests and animal model experiments as well as neurotransmitter expression levels, we further characterize the relationship between olfactory dysfunction and neurodegenerative diseases as well as the molecular mechanisms underlying olfactory dysfunction in the pathology of early-stage Parkinson's disease. The findings highlighted in this review suggest that olfactory dysfunction is an important biomarker for preclinical-stage Parkinson's disease. Therefore, therapeutic drugs targeting non-motor symptoms such as olfactory dysfunction in the early stage of Parkinson's disease may prevent or delay dopaminergic neurodegeneration and reduce motor symptoms, highlighting the potential of identifying effective targets for treating Parkinson's disease by inhibiting the deterioration of olfactory dysfunction.

Citing Articles

PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.

Gujral J, Gandhi O, Singh S, Ahmed M, Ayubcha C, Werner T Am J Nucl Med Mol Imaging. 2025; 14(6):371-390.

PMID: 39840378 PMC: 11744359. DOI: 10.62347/AICM8774.

Serum neurotransmitter analysis of motor and non-motor symptoms in Parkinson's patients.

Fan Y, Yang W, Wu W, Wang X, Lin Y, Wu L Front Aging Neurosci. 2024; 16:1423120.

PMID: 39654806 PMC: 11625801. DOI: 10.3389/fnagi.2024.1423120.

Targeting capabilities of engineered extracellular vesicles for the treatment of neurological diseases.

Yang X, Gao X, Jiang X, Yue K, Luo P Neural Regen Res. 2024; 20(11):3076-3094.

PMID: 39435635 PMC: 11881733. DOI: 10.4103/NRR.NRR-D-24-00462.

Magnetic nanobead assisted the dual targets driven fluorescent biosensor based on SPEXPAR and MNAzyme for the olfactory marker protein detection.

Qi J, Cao X, Bao H, Zhang T, Wang Y, Wen Y Mater Today Bio. 2024; 29:101272.

PMID: 39403314 PMC: 11471671. DOI: 10.1016/j.mtbio.2024.101272.

Liposomes as versatile agents for the management of traumatic and nontraumatic central nervous system disorders: drug stability, targeting efficiency, and safety.

Zhang M, Xiang C, Niu R, He X, Luo W, Liu W Neural Regen Res. 2024; 20(7):1883-1899.

PMID: 39254548 PMC: 11691476. DOI: 10.4103/NRR.NRR-D-24-00048.

References

Sharma A, Kumar R, Aier I, Semwal R, Tyagi P, Varadwaj P . Sense of Smell: Structural, Functional, Mechanistic Advancements and Challenges in Human Olfactory Research. Curr Neuropharmacol. 2018; 17(9):891-911. PMC: 7052838. DOI: 10.2174/1570159X17666181206095626. View

Mullol J, Alobid I, Marino-Sanchez F, Quinto L, De Haro J, Bernal-Sprekelsen M . Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open. 2012; 2(6). PMC: 3533119. DOI: 10.1136/bmjopen-2012-001256. View

Wang J, You H, Liu J, Ni D, Zhang Z, Guan J . Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. AJNR Am J Neuroradiol. 2011; 32(4):677-81. PMC: 7965889. DOI: 10.3174/ajnr.A2350. View

Iravani B, Arshamian A, Schaefer M, Svenningsson P, Lundstrom J . A non-invasive olfactory bulb measure dissociates Parkinson's patients from healthy controls and discloses disease duration. NPJ Parkinsons Dis. 2021; 7(1):75. PMC: 8373926. DOI: 10.1038/s41531-021-00220-8. View

Skrzypczak-Wiercioch A, Salat K . Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use. Molecules. 2022; 27(17). PMC: 9457753. DOI: 10.3390/molecules27175481. View

Ye Y, Wang Y, Yang Y, Tao L . Aloperine suppresses LPS-induced macrophage activation through inhibiting the TLR4/NF-κB pathway. Inflamm Res. 2020; 69(4):375-383. DOI: 10.1007/s00011-019-01313-0. View

Deng H, Dodson M, Huang H, Guo M . The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci U S A. 2008; 105(38):14503-8. PMC: 2567186. DOI: 10.1073/pnas.0803998105. View

Af Bjerken S, Stenmark Persson R, Barkander A, Karalija N, Pelegrina-Hidalgo N, Gerhardt G . Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance. Neurochem Int. 2019; 131:104551. DOI: 10.1016/j.neuint.2019.104551. View

Finkelstein D, Billings J, Adlard P, Ayton S, Sedjahtera A, Masters C . The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017; 5(1):53. PMC: 5490188. DOI: 10.1186/s40478-017-0456-2. View

10.

Tsai R, Tsai C, Liu S, Gao J, Kuo Y, Chao P . Maackiain Ameliorates 6-Hydroxydopamine and Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson's Disease in and the SH-SY5Y Cell Line. Int J Mol Sci. 2020; 21(12). PMC: 7352553. DOI: 10.3390/ijms21124455. View

11.

Cheng C, Zhu X . Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway. Life Sci. 2019; 223:120-127. DOI: 10.1016/j.lfs.2019.02.037. View

12.

Kim Y, Lussier S, Rane A, Choi S, Andersen J . Inducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction. Neuroscience. 2010; 172:379-86. PMC: 3010458. DOI: 10.1016/j.neuroscience.2010.10.072. View

13.

Tremblay C, Emrich R, Cavazzana A, Klingelhoefer L, Brandt M, Hummel T . Specific intranasal and central trigeminal electrophysiological responses in Parkinson's disease. J Neurol. 2019; 266(12):2942-2951. DOI: 10.1007/s00415-019-09517-4. View

14.

Bu M, Farrer M, Khoshbouei H . Dynamic control of the dopamine transporter in neurotransmission and homeostasis. NPJ Parkinsons Dis. 2021; 7(1):22. PMC: 7935902. DOI: 10.1038/s41531-021-00161-2. View

15.

Ghosh Dastidar S, Pham M, Mitchell M, Yeom S, Jordan S, Chang A . 4E-BP1 Protects Neurons from Misfolded Protein Stress and Parkinson's Disease Toxicity by Inducing the Mitochondrial Unfolded Protein Response. J Neurosci. 2020; 40(45):8734-8745. PMC: 7643294. DOI: 10.1523/JNEUROSCI.0940-20.2020. View

16.

Stavoe A, Gopal P, Gubas A, Tooze S, Holzbaur E . Expression of WIPI2B counteracts age-related decline in autophagosome biogenesis in neurons. Elife. 2019; 8. PMC: 6634969. DOI: 10.7554/eLife.44219. View

17.

Doty R, Stern M, Pfeiffer C, Gollomp S, Hurtig H . Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992; 55(2):138-42. PMC: 488979. DOI: 10.1136/jnnp.55.2.138. View

18.

Liu J, Zhao M, Zhang Z, Cui L, Zhou X, Zhang W . Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization. Acta Pharmacol Sin. 2020; 41(4):523-534. PMC: 7468333. DOI: 10.1038/s41401-020-0358-x. View

19.

Rey N, Steiner J, Maroof N, Luk K, Madaj Z, Trojanowski J . Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med. 2016; 213(9):1759-78. PMC: 4995088. DOI: 10.1084/jem.20160368. View

20.

Dan X, Wechter N, Gray S, Mohanty J, Croteau D, Bohr V . Olfactory dysfunction in aging and neurodegenerative diseases. Ageing Res Rev. 2021; 70:101416. PMC: 8373788. DOI: 10.1016/j.arr.2021.101416. View